Last reviewed · How we verify
TAO1, oral homeopathic antibodies — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TAO1, oral homeopathic antibodies (TAO1, oral homeopathic antibodies) — Theranor s.p.r.l.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TAO1, oral homeopathic antibodies TARGET | TAO1, oral homeopathic antibodies | Theranor s.p.r.l | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TAO1, oral homeopathic antibodies CI watch — RSS
- TAO1, oral homeopathic antibodies CI watch — Atom
- TAO1, oral homeopathic antibodies CI watch — JSON
- TAO1, oral homeopathic antibodies alone — RSS
Cite this brief
Drug Landscape (2026). TAO1, oral homeopathic antibodies — Competitive Intelligence Brief. https://druglandscape.com/ci/tao1-oral-homeopathic-antibodies. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab